Today's Date: September 21, 2023
Revry and Discover Present The 8th Annual Queer X Awards on National Coming Out Day   •   COSMOSS Partners With Chopra Foundation 'Never Alone' to Support Mental Health Awareness   •   Sendero Health Plans Names Sharon Alvis as Next Chief Executive   •   RazerCon 2023 Lights Up the Global Gaming Community With Groundbreaking Announcements & Exclusive Partnerships   •   TinySuperheroes Celebrates Its 10th Anniversary Outfitting Courageous Kids With Superhero Capes As They Battle Illnesses and Dis   •   Métis Nation within Alberta Citizens elect new President and Citizens' Council, formally becoming the Otipemisiwak M&eacu   •   Lieutenant General, U.S. Army (Retired) Francis M. Beaudette Named Ambassador at PenFed Foundation   •   Orion S.A. Declares Interim Quarterly Dividend   •   Grant Funding Aims to Improve Safety & Security in New Mexico Schools   •   Valent BioSciences Announces Construction of New Oregon Facility   •   Young Travel & Cruises Educational Seminars Offer Upstate SC Travel Enthusiasts a Chance to Learn about Land, River and Sea   •   Sen. Bernie Sanders Addresses Critical Shortage of Black Physicians at the NMA's Professional Development Series   •   Five Cities Join Sunstone Economic Development Challenge @ USC Price   •   QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA   •   Mattel Publishes Latest Citizenship Report Presenting 2022 Progress on ESG Strategy and Goals   •   LeadingAge And Ziegler Release 20th Annual LeadingAge Ziegler LZ 200 Report   •   Church of the Highlands Opens New Huntsville Campus Location   •   Métis Citizens elect new president in first election for new Otipemisiwak Métis Government   •   SmartHelio Named Start-Up of the Year at RE+ Start-Up Live Competition Sponsored by Mercom Capital Group   •   Sean "Diddy" Combs Applauds Black Leaders' Commitment to Defending Democracy, Driving Corporate Diversity at Congressional Black
Bookmark and Share

Massive Bio Launches Revolutionary ChatGPT-Powered Chatbot Platform at ASCO 2023 to Simplify and Expand Access to Oncology Clini

NEW YORK , June 01 /Businesswire/ - Massive Bio, a world-renowned provider of personalized oncology solutions, is set to showcase its groundbreaking GPT4 AI chatbots - AskFiona AI and DrArturo AI at ASCO 2023. These innovative, AI-driven solutions will redefine cancer care, establishing new paradigms in patient and provider engagement and global oncological research.

This press release features multimedia. View the full release here:

Massive Bio Launches Revolutionary ChatGPT-Powered Chatbot Platform at ASCO 2023 to Simplify and Expand Access to Oncology Clinical Trials (Graphic: Business Wire)

Massive Bio Launches Revolutionary ChatGPT-Powered Chatbot Platform at ASCO 2023 to Simplify and Expand Access to Oncology Clinical Trials (Graphic: Business Wire)

“Massive Bio's ChatGPT-powered platform lies at the heart of the transformation in clinical trials. Incorporating AskFiona AI and DrArturo AI will transcend the capabilities of Massive Bio's existing SYNERGY-AI Clinical Trial Matching Solution, thereby heralding a new epoch in personalized oncology solutions. We are thrilled to constantly push the envelope in oncology clinical trial enrollment. By enabling these new solutions Massive Bio aims to further activate patient empowerment, unlock consumerization in healthcare and reduce the reliance to the hospital competency specific healthcare system via the leverage of latest technology advancements such as generative AI. As a cancer patient you should be able to know all your clinical trial choices regardless of where you get your treatment and/or what your financial stability is” said Massive Bio’s Co-founder and CEO, Selin Kurnaz.

Inspired by its own Co-founders and team members, AskFiona AI and DrArturo AI, enables simplicity, speed, improved engagement, and greater access to patients, treating oncologists, site investigators and research coordinators during clinical trial selection and resolution of last mile issues during enrollment.

AskFiona AI, an advanced AI chatbot, serves as a comprehensive guide through the intricacies of clinical trials. By elucidating trial purposes, processes, and assessing patient eligibility, AskFiona AI aims to demystify the world of clinical trials, promoting clarity and fostering informed decision-making to cancer patients.

Adding depth to this patient-focused approach, DrArturo AI functions as an invaluable virtual oncology tool for providers including oncologists and hematologists. Offering detailed, personalized information about specific clinical trials, including treatment details and insurance acceptance, this AI tool aims to ensure patients, their families, and physicians are equipped with all necessary information to make informed decisions.

As a practicing physician and site investigator, Massive Bio’s Co-founder and CMO, Dr. Arturo Loaiza Bonilla stated that “DrArturo AI also offers extensive benefits to site investigators and research coordinators. With its capacity to deliver detailed study explanations, respond to protocol-related queries, and provide access to vital documents and schedules, it is an indispensable asset. Furthermore, its ability to alert research teams about patient-reported outcomes and adverse events ensures a steady flow of crucial information, thus enhancing patient care and accelerating research.”

“Set to make their debut at ASCO 2023, these AI chatbots encapsulate Massive Bio's dedication to employing AI technology to challenge the status quo in oncology. This pioneering approach is poised to transform the landscape of global oncology.” said Massive Bio’s Co-founder and CTO, Cagatay Culcuoglu.

About Massive Bio:

Massive Bio is at the forefront of empowering cancer patients to discover their optimal treatment options. Utilizing AI to enhance equitable access and precision targeting for clinical trial matching, drug matching, and drug development, Massive Bio is committed to breaking down barriers in clinical trial enrollment, fostering value-based oncology decisions, and facilitating data-driven cancer treatment. Serving over three dozen pharmaceutical companies, contract research organizations, and hospital networks, Massive Bio has earned recognition from the National Cancer Institute with an SBIR contract. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries.

We invite you to join us at ASCO 2023 to experience firsthand Massive Bio's revolutionary strides in personalized oncology solutions.

For further details, please visit,, or interact with us on our social media channels.

STORY TAGS: Photo/Multimedia, Conference, Product/Service, New York, Other Health, Software, Research, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Health, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News